Understanding how patients with moderate-to-severe Crohn's disease describe the spectrum of bowel urgency definitions: Results from qualitative research

被引：0
|
作者：
Dubinsky, M. C. [1 ]
Gibble, T. Hunter [2 ]
Stassek, L. [3 ]
Harding, G. [3 ]
Stefan, M. [3 ]
Fikre, T. [3 ]
Bleakman, A. Potts [4 ]
Moses, R. [4 ]
机构：
[1] Icahn Sch Med Mt Sinai, Gastroenterol, New York, NY USA
[2] Eli Lilly & Co, Value Evidence & Outcomes, Indianapolis, IN USA
[3] Evidera, Bethesda, MD USA
[4] Eli Lilly & Co, Med Affairs, Indianapolis, IN USA
来源：
JOURNAL OF CROHNS & COLITIS | 2024年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P759
引用
收藏
页码：I1405 / I1406
页数：2
相关论文
共 50 条
  • [1] UNDERSTANDING HOW PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE DESCRIBE THE SPECTRUM OF BOWEL URGENCY DEFINITIONS: RESULTS FROM QUALITATIVE RESEARCH
    Dubinsky, Marla C.
    Gibble, Theresa H.
    Stassek, Larissa
    Harding, Gale
    Stefan, Marissa
    Fikre, Tsion G.
    Bleakman, Alison Potts
    Moses, Richard
    GASTROENTEROLOGY, 2024, 166 (05) : S855 - S855
  • [2] UNDERSTANDING HOW PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS DESCRIBE THE SPECTRUM OF BOWEL URGENCY DEFINITIONS: RESULTS FROM QUALITATIVE RESEARCH
    Dubinsky, Marla
    Hunter, Theresa
    Stassek, Larissa
    Harding, Gale
    Stefan, Marissa
    Fikre, Tsion
    Bleakman, Alison Potts
    Moses, Richard
    INFLAMMATORY BOWEL DISEASES, 2024, 30 : S78 - S78
  • [3] UNDERSTANDING HOW PATIENTS WITH MODERATE-TOSEVERE ULCERATIVE COLITIS DESCRIBE THE SPECTRUM OF BOWEL URGENCY DEFINITIONS: RESULTS FROM QUALITATIVE RESEARCH
    Dubinsky, Marla
    Hunter, Theresa
    Stassek, Larissa
    Harding, Gale
    Stefan, Marissa
    Fikre, Tsion
    Bleakman, Alison Potts
    Moses, Richard
    GASTROENTEROLOGY, 2024, 166 (03) : S108 - S109
  • [4] How effective is adalimumab for inducing remission in patients with moderate-to-severe Crohn's disease?
    Ghosh, Subrata
    NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2006, 3 (10): : 540 - 541
  • [5] How effective is adalimumab for inducing remission in patients with moderate-to-severe Crohn's disease?
    Subrata Ghosh
    Nature Clinical Practice Gastroenterology & Hepatology, 2006, 3 : 540 - 541
  • [6] Use of antidepressants in patients with moderate-to-severe Crohn's disease
    Lichtenstein, GR
    Colombel, JF
    Yan, S
    Bala, M
    Olson, A
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (10): : S250 - S251
  • [7] Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn's disease
    Tuskey, Anne
    Behm, Brian W.
    CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2014, 7 : 173 - 179
  • [8] The role of vedolizumab in patients with moderate-to-severe Crohn's disease and ulcerative colitis
    Shahidi, Neal
    Bressler, Brian
    Panaccione, Remo
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2016, 9 (03) : 330 - 338
  • [9] Consistency of treatment benefit with infliximab in patients with moderate-to-severe active Crohn's disease
    Vasiliauskas, E
    Targan, S
    Sands, B
    Hanauer, S
    Mayer, L
    Present, D
    Braakman, T
    DeWoody, K
    Schaible, T
    Rutgeerts, P
    GASTROENTEROLOGY, 1999, 116 (04) : A837 - A837
  • [10] Communicating Needs and Features of IBD Experiences (CONFIDE) Survey: Burden and Impact of Bowel Urgency is Similar in PatientsWith Moderate-to-Severe Crohn's Disease and Ulcerative Colitis
    Schreiber, Stefan
    Gibble, Theresa Hunter
    Dubinsky, Marla C.
    Rubin, David T.
    Panaccione, Remo
    Hibi, Toshifumi
    Kayhan, Cem
    Bleakman, Alison Potts
    Panni, Tommaso
    Favia, Angelo D.
    Atkinson, Christian
    Travis, Simon
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S633 - S634
12345